✦ LIBER ✦

Effects of repeated treatment with the dopamine D2/D3 receptor partial agonist aripiprazole on striatal D2/D3 receptor availability in monkeys

✍ Scribed by Czoty, Paul W.; Gage, H. Donald; Garg, Pradeep K.; Garg, Sudha; Nader, Michael A.

Book ID: 121572068
Publisher: Springer
Year: 2013
Tongue: English
Weight: 271 KB
Volume: 231
Category: Article
ISSN: 0033-3158
DOI: 10.1007/s00213-013-3274-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P.3.d.001 In-vitro pharmacology of aripi

P.3.d.001 In-vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors

✍ Y. Tadori; A. Forbes; R. McQuade; T. Kikuchi 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 96 KB

P.4.13 The D2/D3 dopamine receptor parti

P.4.13 The D2/D3 dopamine receptor partial agonist aripiprazole attenuates cue-induced cocaine relapse in rats

✍ V. Roman; I. Gyertyan 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 55 KB

Reinforcing effects of D2 dopamine recep

Reinforcing effects of D2 dopamine receptor agonists and partial agonists in rhesus monkeys

✍ Robert Ranaldi; Zhixia Wang; William L Woolverton 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 120 KB

Sunshine-exposure variation of human str

Sunshine-exposure variation of human striatal dopamine D2/D3 receptor availability in healthy volunteers

✍ Hsiang-Yi Tsai; Kao Chin Chen; Yen Kuang Yang; Po See Chen; Tzung Lieh Yeh; Nan 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 163 KB

Effects of smoking on D2/D3striatal rece

Effects of smoking on D2/D3striatal receptor availability in alcoholics and social drinkers

✍ Daniel S. Albrecht, David A. Kareken, Karmen K. Yoder 📂 Article 📅 2013 🏛 Springer-Verlag 🌐 English ⚖ 229 KB

Antiparkinsonian effects of the novel D3

Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors

✍ Michael P. Hill; Paula Ravenscroft; Steven G. McGuire; Jonathan M. Brotchie; Ala 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB

L-dopa remains the most common treatment for Parkinson's disease. However, there is considerable interest in D3/D2 receptor agonists such as the novel agent S32504, since they exert antiparkinsonian properties in the absence of dyskinesia. An important question concerns the roles of D2 vs. D3 recept